Broad clinical activity of zoledronic acid in osteolytic to osteoblastic bone lesions in patients with a broad range of solid tumors

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 6 SUPPL. 1, 2002, Pages

  Rosen, Lee ^a   Harland, Stephen J ^b   Oosterlinck, Willem ^c  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Bone metastasis; Breast cancer; Prostate cancer; Solid tumor; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; PAMIDRONIC ACID; ZOLEDRONIC ACID;

BONE DEVELOPMENT; BONE DISEASE; BONE LESION; BONE METASTASIS; BONE PAIN; BREAST CANCER; CLINICAL FEATURE; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; HUMAN; KIDNEY CANCER; LUNG CANCER; MULTIPLE MYELOMA; OSTEOLYSIS; PATHOLOGIC FRACTURE; PATIENT CARE; PROSTATE CANCER; SOLID TUMOR;

BONE NEOPLASMS; BONE RESORPTION; BREAST NEOPLASMS; CLINICAL TRIALS; DIPHOSPHONATES; FEMALE; HUMANS; IMIDAZOLES; LUNG NEOPLASMS; MALE; PROSTATIC NEOPLASMS;

EID: 0036899633     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200212001-00004     Document Type: Conference Paper

References (33)

1. Coleman RE. Should bisphosphonates be the treatment of choice for metastatic bone disease? Semin Oncol 2001;28:35-41.
2. Coleman RE. Skeletal complications of malignancy. Cancer 1997;80:1588-94.
3. Mercadante S. Malignant bone pain: Pathophysiology and treatment. Pain 1997;69:1-18.
4. Lipton A. Bisphosphonates and breast carcinoma. Cancer 1997;80:1668-73.
5. Berruti A, Dogliotti L, Bitossi R, et al. Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: Predictive role of bone resorption and formation markers evaluated at baseline. J Urol 2000;164:1248-53.
6. Mundy GR. Metastatic bone disease. In: Bone Remodeling and Its Disorders. 2nd ed. London: Martin Dunitz, Ltd., 1999:123-46.
7. Krimsky WS, Behrens RJ, Kerkvliet GJ. Oncologic emergencies for the internist. Cleve Clin J Med 2002;69:209-10, 213-4, 216-7 passim.
8. Muggia FM. Overview of cancer-related hypercalcemia: Epidemiology and etiology. Semin Oncol 1990;17:3-9.
9. Theriault RL. Hypercalcemia of malignancy: Pathophysiology and implications for treatment. Oncology (Huntingt) 1993;7:47-50; discussion 52-5.
10. Goltzman D, Karaplis AC, Kremer R, et al. Molecular basis of the spectrum of skeletal complications of neoplasia. Cancer 2000;88:2903-8.
11. Urwin GH, Percival RC, Harris S, et al. Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 1985;57:721-3.
12. Shimazaki J, Higa T, Akimoto S, et al. Clinical course of bone metastasis from prostatic cancer following endocrine therapy: Examination with bone x-ray. Adv Exp Med Biol 1992;324:269-75.
13. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 1987;55:61-6.
14. Zekri J, Ahmed N, Coleman RE, et al. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001;19:379-82.
15. Berruti A, Dogliotti L, Gorzegno G, et al. Differential patterns of bone turnover in relation to bone pain and disease extent in bone in cancer patients with skeletal metastases. Clin Chem 1999;45:1240-7.
16. Lipton A, Costa L, Ali S, et al. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 2001;28:54-9.
17. Lipton A, Costa L, Demers LM. Bone markers in osteoporosis and malignancy. Can J Oncol 1995;5(suppl 1):11-5.
18. Demers LM, Costa L, Chinchilli VM, et al. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem 1995;41:1489-94.
19. Paterson AHG. The potential role of bisphosphonates as adjuvant therapy in the prevention of bone metastases. Cancer 2000;88:3038-46.
20. Coleman RE. The clinical use of bone resorption markers in patients with malignant bone disease. Cancer 2002;94:2521-31.
21. Lipton A, Demers L, Curley E, et al. Markers of bone resorption in patients treated with pamidronate. Eur J Cancer 1998;34:2021-6.
22. Rosen L, Gordon D, Tchekmedyian S, et al. Zoledronic acid significantly reduced the occurrence of skeletal related events (SREs) in patients with osteolytic bone metastases from non-small cell lung cancer (NSCLC) and other solid tumors (OST) [Abstract]. Paper presented at: 3rd International Congress on Prevention and Early Detection of Lung Cancer; Aug 9-12, 2001; Reykjavik, Iceland.
23. Rosen L, Gordon D, Tchekmedyian S, et al. Zoledronic acid (Zol) significantly reduces skeletal-related events (SREs) in patients with bone metastases from solid tumors [Abstract 1179]. Proc Am Soc Clin Oncol 2002;21:295a.
24. Lipton A, Colombo-Berra A, Bukowski R, et al. Zometa (zoledronic acid) is effective in preventing and delaying skeletal related events (SREs) in patients with bone lesions secondary to renal cell carcinoma [Abstract]. Presented at: Quebec Urological Association Meeting; November 14-17, 2002; Montreal, Quebec, Canada.
25. Ernst DS, Tannock IF, Venner PM, et al. Randomized placebo controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone alone in patients with hormone refractory prostate cancer (HRPC) and pain: National Cancer Institute of Canada Clinical Trials Group study [Abstract 705]. Proc Am Soc Clin Oncol 2002;21:177a.
26. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 2001;7:377-87.
27. Coleman RE, Rosen L, Gordon D, et al. Zoledronic acid (4 mg) significantly reduces the relative risk of developing a skeletal-related event compared with pamidronate (90 mg) in patients with breast cancer and bone metastasis [Abstract 355]. To be presented at: 25th Annual San Antonio Breast Cancer Symposium; Dec 11-14, 2002, San Antonio, Texas.
28. Saad F, Gleason DM, Murray R, et al, Zoledronic acid reduces skeletal complications in patients with hormone-refractory prostate carcinoma metastatic to bone: A randomized, placebo-controlled trial. J Natl Cancer Inst 2002;94:1458-68.
29. Saad F, Gleason D, Murray R, et al. Zoledronic acid significantly reduces fractures in patients with hormone-refractory prostate cancer metastatic to bone [Abstract 703]. Paper presented at: Annual Meeting of the American Urological Association; May 25-30, 2002; Orlando, Florida.
30. Lipton A, Small E, Saad F, et al. The new bisphosphonate, ZOMETA® (zoledronic acid) decreases skeletal complications in both lytic and blastic lesions: A comparison to pamidronate [Abstract 34]. Cancer Invest 2001;20(suppl):45-7.
31. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1973-1999. Bethesda, MD: National Cancer Institute, 2002. Available at: http://seer.cancer.gov/csr/1973_1999/. Accessed July 22, 2002.
32. Fourneau I, Broos P. Pathologic fractures due to metastatic disease. A retrospective study of 160 surgically treated fractures. Acta Chir Belg 1998;98:255-60.
33. Poor G, Atkinson EJ, Lewallen DG, et al. Age-related hip fractures in men: Clinical spectrum and short-term outcomes. Osteoporos Int 1995;5:419-26.